PDF] Effects of PDE type 5 inhibitors on Left Ventricular Diastolic Dysfunction in Resistant Hypertension

Management of pulmonary hypertension in left heart disease - Alexander Schmeisser, Hagen Schroetter, Ruediger C. Braun-Dulleaus, 2013

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

PDF) Tadalafil-induced improvement in left ventricular diastolic function in resistant hypertension

Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications

Pulmonary Hypertension: A Brief Guide for Clinicians - Mayo Clinic Proceedings

Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study, BMC Cardiovascular Disorders

Feasibility of high-dose tadalafil and effects on insulin resistance in well-controlled patients with type 2 diabetes (MAKROTAD): a single-centre, double-blind, randomised, placebo-controlled, cross-over phase 2 trial - eClinicalMedicine

PDE5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function, Cardiac Geometry, and Clinical Status in Patients With Stable Systolic Heart Failure

Cilostazol ameliorates heart failure with preserved ejection fraction and diastolic dysfunction in obese and non-obese hypertensive mice - Journal of Molecular and Cellular Cardiology

Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease - Tzoumas - 2020 - British Journal of Pharmacology - Wiley Online Library

Sildenafil preserves diastolic relaxation after reduction by L-NAME and increases phosphodiesterase-5 in the intercalated discs of cardiac myocytes and arterioles

Assessment and Prognostic Impact of Right Ventricular Function in Patients with Pulmonary Arterial Hypertension Undergoing Pulmonary Artery Denervation: Central Role of Global Right Ventricular Longitudinal Peak Systolic Strain* - Structural Heart

JAMA-PDE5i in heart failure

Treatment Selection in Pulmonary Arterial Hypertension: Phosphodiesterase Type 5 Inhibitors versus Soluble Guanylate Cyclase Stimulator